As if these commercials weren't horrific enough, the product they are advertising is the most blatant example of deceptive marketing for a drug that can ONLY cause more harm than benefit in any user taking it.

The claims made by Jardiance ads, that it “slows the progression of CKD” and “reduces the risk of kidney failure”, are carefully constructed marketing based on relative statistical endpoints from pharma-sponsored trials, not on long-term proof of renal healing. 

No chemical ingestion can logically improve kidney health. The chemicals introduced by the synthetic compound must be detoxified via glomeruli/tubules... burdening the very organ they allegedly claim to benefit.

Jardiance is a synthetic SGLT2 inhibitor, originally created to force excess glucose excretion via urine, increasing osmotic diuresis. So while it reduces glomerular hyperfiltration at first, chronic use increases exposure to osmotic stress, electrolyte loss, and dehydration.

No kidney cell or filtration membrane is healed by this drug. Instead, damage is masked by short-term functional metrics (e.g., eGFR slope), while underlying cellular and mitochondrial dysfunction is unaddressed. The drug companies claim this drug benefits health by comparing metrics in test results, not by showing reversal or structural recovery.

Jardiance may reduce certain lab metrics short-term but introduces long-term load on mitochondrial energy systems, detox pathways, and cellular integrity.

The FDA warning labels lists all of these risks:

  • Euglycemic ketoacidosis: Can lead to ICU admission even with normal blood sugar
  • Fungal urinary infections: Elevated glucose in urine creates a breeding ground
  • Acute kidney injury (AKI): Especially in dehydrated or elderly patients
  • Volume depletion: Leading to dizziness, hypotension, or worse
  • Bone fracture and limb amputation risk: Observed in SGLT2 class

Yet they’re not presented in the marketing, nor is the fact that long-term renal survival advantage remains unproven.

Eli Lilly and Boehringer Ingelheim’s Jardiance consistently ranks in top‑10 highest TV‑ad spending in 2024, with nearly $18.9 million on TV ads in May alone (up from $16.4 million in April). Across the 10 most‑advertised drugs, total TV ad spend exceeded $2.13 billion in 2024.

No publicly documented Jardiance‑specific marketing budget exceeds corporate totals, but Eli Lilly’s average ad spend exceeds $1 billion per year, much of it promoting Jardiance alongside other drugs.

The ratio of marketing to independent long‑term safety research is stark.

The phase III trials for Jardiance used a median follow‑up of ~2  years to claim benefits, which is insane and completely fails to assess long term:

  • Cumulative mitochondrial or tubular damage
  • Renal cellular aging, fibrosis, nephron dropout
  • Late-onset adverse events, particularly in polypharmacy contexts
  • Long-term mortality or functional survival benefit beyond surrogate endpoints (eGFR decline ≥40%, ESRD)

Given kidneys load toxins over decades, two years is totally inadequate to validate tissue integrity or assess real-world harm trajectories.

0:00
/0:12
0:00
/0:11

From FDA prescribing information and public resources, every adverse effect listed:

WARNINGS / PRECAUTIONS

  • Volume depletion leads to symptomatic hypotension; acute creatinine rises; risk of AKI, hospitalization, dialysis in at-risk populations 
  • Urosepsis and pyelonephritis leads to serious UTIs requiring hospitalization FDA Access DataFDA Access Data
  • Hypoglycemia when combined with insulin/secretagogues; pediatric risk above age 10 even without insulin FDA Access DataFDA Access Data
  • Fournier’s gangrene (necrotizing fasciitis of perineum); hospitalizations, multiple surgeries, death FDA Access DataFDA Access Data
  • Genital mycotic infections (vaginal yeast; penile balanitis/balanoposthitis), especially recurrent cases 
  • Lower‑limb amputation risk increased modestly (HR 1.05), events higher in PAD or foot ulcer history FDA Access DataFDA Access Data
  • Hypersensitivity reactions (angioedema, serious allergic reactions) FDA Access DataFDA Access Data
  • LDL‑cholesterol increases FDA Access DataFDA Access Data

ADVERSE REACTIONS
From clinical trials and post‑marketing: